stiripentol
Trade name: diacomit
Approved
Aug 20, 2018
Stiripentol is an anticonvulsant drug used in the treatment of epilepsy. It recently proved to increase the GABAergic transmission in vitro in an experimental model of immature rat. Clinical studies were based on the fact that STP also acts as an inhibitor of CYP3A4, CYP1A2, and CYP2C19 in vivo in epileptic patients. Side effects are largely due to the increase in plasma concentrations of other anticonvulsants and can be reduced by lowering the dose of those drugs. Nausea and vomiting are particularly noted when used in combination with sodium valproate. It appears to increase the potency of phenobarbital, primidone, phenytoin, carbamazepine, clobazam and diazepam. — NCATS
Clinical trial activity
10 trials · 10 clinical orgs · 1 marketing orgs
Earliest trial started Feb 1, 2012 (NCT01533506)
Timeline
2000s
- Oct 30, 2008
Orphan Drug Designation
2010s
Indications
Approved for
Mechanism of action
- GABA-A receptorAGONIST
GABA-A receptor agonist
- Unspecified targetOTHER
Unknown
Possible effects include GABA receptor modulation, L-lactate dehydrogenase inhibition or cytochrome P450 inhibition (resulting in increased levels of co-administered clobazam).
Approval history
- approvedPriority reviewAug 20, 2018
Chemistry & pharmacology
SMILES
CC(C)(C)C(O)C=CC1=CC=C2OCOC2=C1- Mol. weight
- 234.2909 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaStiripentol ↗
- NCATSR02XOT8V8I ↗
- ChEMBLCHEMBL1983350 ↗
Also known as
- 1-(1,3-benzodioxol-5-yl)-4,4- dimethyl-1-penten-3-ol
- 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol
- 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol
- 4,4-dimethyl-1-((3,4-methylenedioxy)phenyl)-1-penten-3-ol
- 4,4-dimethyl-1-((3,4-methylenedioxy)phenyl)-1-penten-3-ol
- bcx 2600
- bcx 2600
- bcx-2600
- bcx-2600
- brn 1313047
- brn 1313047
- d-306
- diacomit
- diacomit
- diacomit
- estiripentol
- estiripentol
- estiripentol
- estiripentol
- estiripentol
- stiripentol
- stiripentol
- stiripentol
- stiripentol
- stiripentol
- stiripentol
- stiripentol
- stiripentol
- stiripentol
- stiripentol
- stiripentolum
- stiripentolum
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07176832 | Phase 1 | Jun 1, 2025 | Biocodex |
| NCT06465472 | Phase 3 | Aug 31, 2024 | Biocodex, Exystat, Monopar Therapeutics |
| NCT05735951 | Phase 1 | Mar 25, 2023 | Biocodex, Comac Medical |
| NCT05419180 | Phase 4 | Oct 13, 2022 | Biocodex |
| NCT03819647 | Phase 2 | May 31, 2019 | Biocodex |
| NCT03866928 | Phase 1 | Feb 12, 2019 | Biocodex |
| NCT02239276 | N/A | Sep 10, 2014 | Cook Children's Health Care System, Cook Children's Medical Center |
| NCT01983722 | N/A | Nov 7, 2013 | University of Cincinnati |
| NCT01835314 | N/A | Apr 15, 2013 | University of Colorado, University of Colorado, Denver |
| NCT01533506 | N/A | Feb 1, 2012 | Mayo Clinic |
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biocodex | For profit | 6 | 6 | 4 | 2019 |
| Comac Medical | For profit | 1 | 0 | 1 | 2023 |
| Cook Children's Health Care System | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Cook Children's Medical Center | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Exystat | For profit | 1 | 0 | 1 | 2024 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Monopar Therapeutics | For profit | 1 | 0 | 1 | 2024 |
| University of Cincinnati | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Colorado | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Colorado, Denver | Academic/Hospital | 1 | 1 | 1 | 2013 |